| Literature DB >> 30213925 |
Shengqing Hu1, Yunfei Liao1, Lulu Chen1.
Abstract
BACKGROUND To provide a better understanding of anaplastic thyroid carcinoma (ATC) at the molecular level, this study aimed to identify the genes and key pathways associated with ATC by using integrated bioinformatics analysis. MATERIAL AND METHODS Based on the microarray data GSE9115, GSE65144, and GSE53072 derived from the Gene Expression Omnibus, the differentially expressed genes (DEGs) between ATC samples and normal controls were identified. With DEGs, we performed a series of functional enrichment analyses. Then, a protein-protein interaction (PPI) network was constructed and visualized, with which the hub gene nodes were screened out. Finally, modules analysis for the PPI network was performed to further investigate the potential relationships between DEGs and ATC. RESULTS A total of 537 common DEGs were screened out from all 3 datasets, among which 247 genes were upregulated and 275 genes were downregulated. GO analysis indicated that upregulated DEGs were mainly involved in cell division and mitotic nuclear division and the downregulated DEGs were significantly enriched in ventricular cardiac muscle cell action potential. KEGG pathway analysis showed that the upregulated DEGs were mainly enriched in cell cycle and ECM-receptor interaction and the downregulated DEGs were mainly enriched in thyroid hormone synthesis, insulin resistance, and pathways in cancer. The top 10 hub genes in the constructed PPI network were CDK1, CCNB1, TOP2A, AURKB, CCNA2, BUB1, AURKA, CDC20, MAD2L1, and BUB1B. The modules analysis showed that genes in the top 2 significant modules of PPI network were mainly associated with mitotic cell cycle and positive regulation of mitosis, respectively. CONCLUSIONS We identified a series of key genes along with the pathways that were most closely related with ATC initiation and progression. Our results provide a more detailed molecular mechanism for the development of ATC, shedding light on the potential biomarkers and therapeutic targets.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30213925 PMCID: PMC6151107 DOI: 10.12659/MSM.910088
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Identification results of differentially expressed genes in gene expression profiling datasets GSE53072, GSE65144, and GSE9115. (A) Upregulated DEGs of 3 datasets, (B) Downregulated DEGs of 3 datasets, (C) DEGs of the 3 data sets.
Figure 2Heat map plots of differentially expressed genes across 3 gene expression profiles. (A–C) Heat maps of overlapped DEGs observed in datasets GSE9115, GSE53072 and GSE 65144, respectively. NC – normal control, ATC – anaplastic thyroid carcinoma.
Gene ontology analysis of differentially expressed genes associated with anaplastic thyroid cancer.
| Category | Term | Count | % | P value |
|---|---|---|---|---|
| GOTERM_BP_DIRECT | GO: 0051301~cell division | 29 | 0.073774454 | 8.89E-14 |
| GOTERM_BP_DIRECT | GO: 0007067~mitotic nuclear division | 20 | 0.050878934 | 2.14E-09 |
| GOTERM_BP_DIRECT | GO: 0007155~cell adhesion | 24 | 0.06105472 | 1.32E-07 |
| GOTERM_BP_DIRECT | GO: 0007229~integrin-mediated signaling pathway | 12 | 0.03052736 | 1.36E-07 |
| GOTERM_BP_DIRECT | GO: 0000082~G1/S transition of mitotic cell cycle | 12 | 0.03052736 | 1.86E-07 |
| GOTERM_CC_DIRECT | GO: 0000776~kinetochore | 12 | 0.03052736 | 9.65E-09 |
| GOTERM_CC_DIRECT | GO: 0016020~membrane | 56 | 0.142461014 | 2.23E-06 |
| GOTERM_CC_DIRECT | GO: 0005615~extracellular space | 40 | 0.101757867 | 3.20E-06 |
| GOTERM_CC_DIRECT | GO: 0005925~focal adhesion | 18 | 0.04579104 | 1.99E-05 |
| GOTERM_CC_DIRECT | GO: 0000777~condensed chromosome kinetochore | 9 | 0.02289552 | 2.04E-05 |
| GOTERM_MF_DIRECT | GO: 0005515~protein binding | 160 | 0.407031469 | 2.37E-06 |
| GOTERM_MF_DIRECT | GO: 0005524~ATP binding | 42 | 0.106845761 | 2.64E-05 |
| GOTERM_MF_DIRECT | GO: 0005178~integrin binding | 9 | 0.02289552 | 1.19E-04 |
| GOTERM_MF_DIRECT | GO: 0005518~collagen binding | 7 | 0.017807627 | 1.95E-04 |
| GOTERM_MF_DIRECT | GO: 0004872~receptor activity | 12 | 0.03052736 | 2.65E-04 |
| GOTERM_BP_DIRECT | GO: 0086005~ventricular cardiac muscle cell action potential | 4 | 0.011480265 | 2.30E-04 |
| GOTERM_BP_DIRECT | GO: 0014066~regulation of phosphatidylinositol 3-kinase signaling | 7 | 0.016072372 | 0.00136878 |
| GOTERM_BP_DIRECT | GO: 0030318~melanocyte differentiation | 5 | 0.009184212 | 0.001486948 |
| GOTERM_BP_DIRECT | GO: 0033539~fatty acid beta-oxidation using acyl-CoA dehydrogenase | 4 | 0.009184212 | 0.002576085 |
| GOTERM_BP_DIRECT | GO: 0009083~branched-chain amino acid catabolic process | 4 | 0.009184212 | 0.003024104 |
| GOTERM_CC_DIRECT | GO: 0070062~extracellular exosome | 77 | 0.176796088 | 9.63E-08 |
| GOTERM_CC_DIRECT | GO: 0016324~apical plasma membrane | 16 | 0.036736849 | 3.52E-05 |
| GOTERM_CC_DIRECT | GO: 0042383~sarcolemma | 8 | 0.018368425 | 2.86E-04 |
| GOTERM_CC_DIRECT | GO: 0016323~basolateral plasma membrane | 11 | 0.025256584 | 3.96E-04 |
| GOTERM_CC_DIRECT | GO: 0005856~cytoskeleton | 16 | 0.036736849 | 5.10E-04 |
| GOTERM_MF_DIRECT | GO: 0005516~calmodulin binding | 12 | 0.027552637 | 1.40E-04 |
| GOTERM_MF_DIRECT | GO: 0052890~oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor | 4 | 0.009184212 | 0.001339754 |
| GOTERM_MF_DIRECT | GO: 0005200~structural constituent of cytoskeleton | 8 | 0.018368425 | 0.001372584 |
| GOTERM_MF_DIRECT | GO: 0003995~acyl-CoA dehydrogenase activity | 4 | 0.009184212 | 0.001630695 |
| GOTERM_MF_DIRECT | GO: 0044325~ion channel binding | 7 | 0.016072372 | 0.007246827 |
The top 10 enriched KEGG pathways of differentially expressed genes associated with anaplastic thyroid cancer.
| Pathway ID/Name | Count | % | P Value | Genes |
|---|---|---|---|---|
| hsa04110: Cell cycle | 14 | 0.035615254 | 6.15E-07 | CDC7, CDC6, MAD2L1, CCNB2, YWHAH, BUB1, TTK, BUB1B, CHEK1, CCNA2, MCM4, MYC, MCM5, MCM6 |
| hsa04512: ECM-receptor interaction | 9 | 0.02289552 | 2.49E-04 | COL3A1, ITGB5, ITGA2, ITGA4, ITGB1, COL5A1, SPP1, FN1, HMMR |
| hsa05140: Leishmaniasis | 8 | 0.020351573 | 3.99E-04 | IRAK1, MYD88, TLR2, FCGR2A, ITGA4, STAT1, ITGB1, ITGAM |
| hsa05205: Proteoglycans in cancer | 12 | 0.03052736 | 0.001565479 | CASP3, HPSE, MMP9, TLR2, ITGB5, ITGA2, MYC, ITGB1, PLAU, FN1, TWIST1, PLAUR |
| hsa04151: PI3K-Akt signaling pathway | 16 | 0.040703147 | 0.002476592 | IL2RA, COL3A1, TLR2, ITGB5, ITGA2, ITGA4, ITGB1, COL5A1, EIF4EBP1, YWHAH, IL4R, MYC, SPP1, FN1, CSF1R, F2R |
| hsa04145: Phagosome | 10 | 0.025439467 | 0.00265876 | CYBB, FCGR2B, TLR2, ITGB5, ITGA2, FCGR2A, CTSS, TUBA1A, ITGB1, ITGAM |
| hsa04611: Platelet activation | 9 | 0.02289552 | 0.003464929 | ADCY7, COL3A1, ITGA2, FCGR2A, ITGB1, VASP, COL5A1, LCP2, F2R |
| hsa04380: Osteoclast differentiation | 9 | 0.02289552 | 0.003631749 | CYBB, FCGR2B, LILRB4, FCGR2A, TREM2, STAT1, CSF1R, LCP2, TYROBP |
| hsa03030: DNA replication | 5 | 0.012719733 | 0.004794752 | POLE2, MCM4, MCM5, FEN1, MCM6 |
| hsa04666: Fc gamma R-mediated phagocytosis | 7 | 0.017807627 | 0.00540983 | ARPC1B, FCGR2B, RAC2, HCK, WASF1, FCGR2A, VASP |
| hsa04918: Thyroid hormone synthesis | 7 | 0.016072372 | 0.001859153 | SLC26A4, PLCB4, ADCY9, PAX8, ATP1A1, LRP2, ITPR1 |
| hsa05202: Transcriptional misregulation in cancer | 9 | 0.020664478 | 0.013054046 | HHEX, NUPR1, ID2, CCND2, PAX8, ARNT2, TSPAN7, PBX1, MLLT3 |
| hsa04931: Insulin resistance | 7 | 0.016072372 | 0.015302523 | PRKCQ, PIK3CB, RPS6KA2, TBC1D4, IRS1, PPARGC1A, SLC27A2 |
| hsa04015: Rap1 signaling pathway | 10 | 0.022960531 | 0.016414205 | FGFR2, PLCB4, MAGI1, ADCY9, PIK3CB, EFNA1, VEGFA, CDH1, KIT, RAPGEF3 |
| hsa04972: Pancreatic secretion | 6 | 0.013776319 | 0.02955826 | PLCB4, ADCY9, RYR2, ATP1A1, SLC4A4, ITPR1 |
| hsa05200: Pathways in cancer | 14 | 0.032144743 | 0.031228341 | FGFR2, PIK3CB, ARNT2, FZD3, CDH1, KIT, DAPK2, EDNRB, FOS, PLCB4, ADCY9, BCL2, PAX8, VEGFA |
| hsa04960: Aldosterone-regulated sodium reabsorption | 4 | 0.009184212 | 0.035652255 | PIK3CB, ATP1A1, SCNN1A, IRS1 |
| hsa04020: Calcium signaling pathway | 8 | 0.018368425 | 0.049708184 | EDNRB, GNAL, PLCB4, ADCY9, ERBB3, PDE1A, RYR2, ITPR1 |
Figure 3Protein–protein interaction networks for all DEGs.
Figure 4Top 10 hub genes in protein–protein interaction networks.
Figure 5Top 2 significant modules from the protein–protein interaction network.
GO enrichment analysis of module 1 from the protein–protein interaction network.
| GO-ID | p Value | Description | Genes in test set |
|---|---|---|---|
| 278 | 1.82E-08 | Mitotic cell cycle | CDC20|CDC45|NUF2|CDK1|MCM10|BUB1|NDC80 |
| 22402 | 1.84E-08 | Cell cycle process | CDC20|CDC45|EXO1|NUF2|CDK1|MCM10|BUB1|NDC80 |
| 7049 | 6.68E-08 | Cell cycle | CDC20|CDC45|EXO1|NUF2|CDK1|MCM10|BUB1|NDC80 |
| 22403 | 1.76E-07 | Cell cycle phase | CDC20|CDC45|NUF2|CDK1|MCM10|BUB1|NDC80 |
| 7067 | 2.29E-06 | Mitosis | CDC20|NUF2|CDK1|BUB1|NDC80 |
| 87 | 2.41E-06 | M phase of mitotic cell cycle | CDC20|NUF2|CDK1|BUB1|NDC80 |
| 280 | 2.98E-06 | Nuclear division | CDC20|NUF2|CDK1|BUB1|NDC80 |
| 48285 | 3.84E-06 | Organelle fission | CDC20|NUF2|CDK1|BUB1|NDC80 |
| 226 | 9.12E-06 | Microtubule cytoskeleton organization | CDC20|NUF2|BUB1|NDC80 |
| 7017 | 1.60E-05 | Microtubule-based process | CDC20|NUF2|BUB1|NDC80 |
| 45787 | 3.91E-05 | Positive regulation of cell cycle | CDC20|CDK1 |
GO enrichment analysis of module 2 from the protein–protein interaction network.
| GO-ID | p Value | Description | Genes in test set |
|---|---|---|---|
| 45840 | 3.22E-04 | Positive regulation of mitosis | CDH1 |
| 45842 | 3.22E-04 | Positive regulation of mitotic metaphase/anaphase transition | CDH1 |
| 51488 | 3.22E-04 | Activation of anaphase-promoting complex activity | CDH1 |
| 45862 | 3.22E-04 | Positive regulation of proteolysis | CDH1 |
| 51785 | 3.22E-04 | Positive regulation of nuclear division | CDH1 |
| 32436 | 3.22E-04 | Positive regulation of proteasomal ubiquitin-dependent protein catabolic process | CDH1 |
| 7092 | 3.22E-04 | Activation of mitotic anaphase-promoting complex activity | CDH1 |
| 10697 | 3.22E-04 | Negative regulation of spindle pole body separation | CDH1 |
| 51437 | 3.22E-04 | Positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle | CDH1 |
| 32434 | 4.83E-04 | Regulation of proteasomal ubiquitin-dependent protein catabolic process | CDH1 |